<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661958</url>
  </required_header>
  <id_info>
    <org_study_id>SGT-65-02</org_study_id>
    <nct_id>NCT02661958</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sol-Gel Technologies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sol-Gel Technologies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority in efficacy and assess safety and
      tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active
      components or the vehicle for the treatment of acne.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>week 12</time_frame>
    <description>Proportion of subjects with an assessment of clear or almost clear with at least a 2-grade improvement in IGA at Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in lesion count (separately for inflammatory and non-inflammatory)</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Absolute change from Baseline in lesion count on the face at Week 12 (separately for inflammatory and non-inflammatory lesions)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from Baseline in lesion count on the face at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Percentage change from Baseline in lesion count on the face at Week 12 (separately for inflammatory and non-inflammatory lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessments of IGA at each time point</measure>
    <time_frame>baseline, week 4, 8</time_frame>
    <description>Supportive efficacy variables are the assessments of IGA percentage change at each time point during the treatment period, namely at Weeks 4, and 8.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>S6G5T-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-3</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-1</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-5</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-6</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-7</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-8</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects 9 years of age or older.

          2. In good general health Based on medical records

          3. Have a diagnosis of facial acne with &gt;25 and &lt;100 non-inflammatory lesions and &gt;20 and
             &lt;50 inflammatory lesions.

          4. Have a score of &quot;3&quot; or &quot;4&quot; (Moderate or Severe) on the IGA scale.

          5. Have two or fewer cysts or nodules (defined as an inflammatory lesion greater than or
             equal to 5 mm in diameter).

          6. Sexually active women of child-bearing potential must use one of the following birth
             control options:

             One of these highly effective contraception methods:

             i. Intrauterine device (IUD); ii. Hormonal, for at least 3 months (Pills, injections,
             implants, transdermal patch, vaginal ring); iii. Tubal ligation; iv. Partner
             vasectomy,

          7. OR A barrier form of contraception (listed below) i. Male or female condom; ii.
             Diaphragm with spermicides; iii. Cervical cap with spermicides; iv. Contraceptive
             sponge

          8. Willingness and capacity for protocol compliance (for subjects under the age of
             consent, the parent/guardian must be willing and able to comply with study
             requirements).

          9. Male subjects must be clean-shaven and agree to remain so for during the study visits.

         10. Consent to participate, verified by signing an approved written Informed Consent Form
             and HIPAA; for subjects under the age of consent, both a signed assent form and a
             signed Informed Consent Form from the parent/guardian are required in accordance with
             local and federal regulations.

        Exclusion Criteria:

          1. More than two acne nodules or cysts (defined as an inflammatory lesion greater than or
             equal to 5 mm in diameter)

          2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc or
             severe acne requiring systemic treatment.

          3. Underlying disease that requires the use of interfering topical or systemic therapy.

          4. Other dermatological conditions that require the use of interfering topical or
             systemic therapy or that might interfere with study assessments such as, but not
             limited to, atopic dermatitis, perioral dermatitis, or rosacea.

          5. Beard, facial hair, or tattoo that may interfere with study assessments.

          6. Use of tanning booths or tanning lamps within one week prior to Baseline and an
             unwillingness to refrain from use during the study.

          7. Use of hormonal contraceptives, unless subject is on a stable dose for at least three
             months prior to enrollment.

          8. Use of hormonal contraceptives solely for the control of acne.

          9. Use of prohibited medications prior to the study and unwillingness to refrain from use
             during the study.

         10. Known sensitivities to the study drug ingredients. Allergy to benzoyl peroxide,
             tretinoin, parabens and glycerin or other ingredients listed in the investigator
             brochure.

         11. Clinically significant abnormal findings or conditions (other than acne), which might,
             in the opinion of the investigator, interfere with study evaluations or pose a risk to
             subject safety during the study.

         12. Female subjects who are pregnant and/or nursing or planning to become pregnant during
             the course of the trial. Subjects who test positive for pregnancy after start of test
             treatment will be discontinued from test treatment but will be followed for safety
             purposes.

         13. Participation in another investigational drug or device research study within 30 days
             of enrollment or five half-lives of the drug, whichever is longer.

         14. Current or history of facial skin cancer.

         15. Is an employee or family member of the study investigator or other study staff having
             direct involvement in the proposed study.

         16. Is a family member of a study participant recruited and enrolled into the proposed
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piyush Sheladia, M.S.</last_name>
    <role>Study Chair</role>
    <affiliation>Accelovance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T. Joseph Raoof MD, Inc./Encino Research Center</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center, LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MOORE Clinical Research, Inc</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LCC Medical Research Institute, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oceane7 Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RM Medical Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIC Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Core Healthcare Group</name>
      <address>
        <city>Cerritos</city>
        <state>Louisiana</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSearch clinical Trials</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research, Inc.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>3801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research Center of New York, Inc</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Co, Inc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services, LLC @ Greenville Dermatology</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Research, Inc.</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

